Isoniazid acetylation phenotyping in the Japanese: The molar metabolic ratio INH/AcINH

American Journal of Therapeutics

Volumn 3, Issue 1, 1996, Pages 74-78

  Kohno, Haruichi ^a,b,d   Kubo, Hiroaki ^a   Takada, Atsushi ^a   Mori, Masashi ^b   Arias, T D ^c  

^a KITASATO UNIVERSITY   (Japan)

^b National Tokyo Chest Hospital   (Japan)

^c Univerdidad de Panama   (Panama)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

acetylator phenotype; antimode; genetic polymorphism; isoniazid; Japanese; metabolic ratio

Indexed keywords

ISONIAZID;

ADULT; AGED; ARTICLE; DRUG ACETYLATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG URINE LEVEL; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; HUMAN; JAPAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PHENOTYPE; PRIORITY JOURNAL; RACE DIFFERENCE;

EID: 0030030497     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-199601000-00010     Document Type: Article

References (28)

1. Evans DAP: Genetic Factors in Drug Therapy - Clinical and Molecular Pharmncogenetics, Cambridge University Press, Cambridge, 1993, pp. 211-302.
2. Miller JA, Miller EC: The metabolic activation of carcinogenic aromatic amines and amides. Prog Exp Tumor Res 1969;II:273-280.
3. Sunahara S, Urano M, Ogawa M, Yoshida S, Mukoyama H, Kawai K: Genetical aspect of isoniazid metabolism. Jpn J Hum Genet 1963;8:93-111.
4. Evans DAP, Manley KA, McKusick VA: Genetic control of isoniazid metabolism in man. Br Med J 1960;2:485-461.
5. Sunahara S, Urano M, Ogawa M: Genetical and geographic studies on isoniazid inactivation. Science 1961; 134:1531-1531.
6. Ellard GA: Variations between individuals and populations in the acetylation of isoniazid and its significance for the treatment of pulmonary tuberculosis. Clin Pharmacol Ther 1976;19:610-625.
7. Lunde PKM, Frislid K, Hansteen V: Disease and acetylation polymorphism. Clin Pharmacokinet 177;2:182-197.
8. Reidenberg MM, Martin JH: The acetylator phenotype of patient with systemic lupus erythematosus. Drug Metab Dispos 1974;2:71-73.
9. Horai Y, Ishizaki T, Sasaki T, Koya G, Matsuyama T, Iguchi S: Isoniazid disposition, comparison of isoniazid phenotyping in and acetylator distribution of Japanese patients with idiopathic Lupus erythematosus and control subjects. Br J Clin Pharmacol 1988;13:361-374.
10. Lower GM Jr, Nelsson T, Nelson CE, Wolf H, Gamsky TE, Bryan GT: N-Acetyltransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology. Preliminary results in Sweden and Denmark. Environ Hlth Perspect 1979;29:71-79.
11. Horai Y, Fujita K, Ishizaki T: Genetically determined N-acetylation and oxidation capacities in Japanese patients with non-occupational urinary bladder cancer. Eur J Clin Pharmacol 1989;37:581-587.
12. Inaba T, Arias TD: On phenotyping with isoniazed: the use of urinary acetylation ratio and the uniqueness of antimodes. Study of two Amerindian populations. Clin Pharmacol Ther 1987;42:493-497.
13. Deguchi T, Mashimo M, Suzuki T: Correlation between acetylator phenotypes of polymorphic arylamine N-acetyltransferase in human liver. J Biol Chem 1990;265: 12757-12760.
14. Arias TD, Jorge LF, Griese EU, Inaba T, Eichelbaum M: Polymorphic N-acetyltransferase (NAT2) in Amerindians population of Panama and Columbia: high frequencies of point mutation 857A, as found in allele S3/M3. Pharmacogenetics 1993;3:328-331.
15. Kohno H, Kubo H, Furukawa K, Yoshino N, Nishikawa T: Fluorometric determination of isoniazid and its metabolites in urine by high-performance liquid chromatography using in-line derivatization. Ther Drug Monit 1991;13:428-432.
16. Eidus L, Harnanansingh AMT, Jessamine AG: Urine test for phenotyping isoniazid inactivators. Am Rev Respir Dis 1971;104:587-591.
17. Venkataraman P, Menon NK, Nair NGK, Radhakrishna S, Ross C, Tripathy SP: Classification of subjects as slow or rapid inactivators of isoniazid, based on the ratio of the urinary excretion of acetylisoniazid to isoniazid. Tubercle 1972;53:84-91.
18. Mahgrub A, Idle JR, Dring LG, Lancaster R, Smith RL: Polymorphic hydroxylation of debrisoquine in man. Lancet 1977;ii:584-586.
19. Evans DAP, Mahgrob A, Sloan TP, Idle JR, Smith RL: A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Mod Genet 1980;17:102-105.
20. Iyun AO, Med M, Lennard MS, Woods HF: Metoprolol and debrisdquine metabolism in Nigerians: Lack of evidence for polymorphic oxidation. Clin Pharmacol Ther 1986;40:387-394.
21. Lennard MS, Iyun AO, Jackson PR, Woods HF: Evidence for a dissociation in the control of sparteine, debrisoquine, and metoprolol metabolism in Nigerians. Pharmacogenetics 1992;2:89-92.
22. Arias TD, Inaba T, Cooke RG, Jorge LF: A preliminary note on the transient polymorphic oxidation of sparteine in the Ngawbé Guaymí Amerindians: a case of genetic divergence with tentative phylogenetic time frame for the pathway. Clin Pharmacol Ther 1988;44:343-352.
23. Maston GA, Sutton HE, Swanson J, Robinson AR: Distribution of haptoglobin, transferrin, and hemoglobin types among Indians of Middle America in British Hounduras, Costa Rica and Panama. Am J Phys Anthropol 1965;23: 387-394.
24. Tannis RJ, Neel JV, de Arauz RT: Two more "private" polymorphisms of Amerindian tribes: LDHBGUA-1 and ACP GUA-1 in the Guaymi in Panama. Am J Hum Genet 1977;29:419-430.
25. Barrantes R, Smouse PE, Neel JV, Mohrenweiser HW, Gershowitz H: Migration and genetic infrastructure of the Central American Guaymí and their affinities with other tribal groups. Am J Phys Anthropol 1982;58:201-214.
26. Cavalli-Sforza LL, Piazza A, Menozzi P, Mountain J: Reconstruction of human evolution: bringing together genetic, archaeological, and linguistic data. Proc Natl Acad Sci USA 1988;85:6002-6006.
27. Horai S, Kondo R, Nakagawa-Hattori Y, Hayashi S, Sonoda S, Tajima K: Peopling of the Americas, founded by four major linegages of mitochondrial DNA. Mol Biol Evol 1993;10:23-47.
28. Lin HJ, Han CY, Lin BK, Hardy S: Slow acetylator mutations in the human polymorphic N-acetyltransferase gene in 786 asians, blacks, hispanics, and whites: Application to metabolic epidemiology. Am J Hum Genet 1993;52:827-834.